SpliSense is currently conducting a Phase IIb trial with its antisense oligonucleotide therapy.

It's important to consider your comfort with risk before diving in.

Domestic pharmaceutical and biotech companies’ technology exports are growing rapidly this year as well. With cumulative ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking ...

While SpaceX dazzles with a $2 trillion valuation, Massachusetts’ biotech sector is quietly stacking wins that save lives and ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Sources: FactSet, Dow Jones Stock Movers: Gainers, ...

Cogent Biosciences is positioned to build a niche KIT-mutant franchise, leveraging bezuclastinib across three pivotal ...

Biotech firms develop drugs from living organisms; pharma from chemicals. Biotech products require a Biologics License Application for FDA approval. Investing focus should be on the long-term ...

Orders reinforce strong demand outlook in global health markets and supports 2026 revenue and profitability targets ...

The investment seeks is to achieve 3 times (300%) the income generated from selling options on the S&P Biotechnology Select Industry Index (the “underlying index”) by selling options on leveraged ...